International Psoriasis Council
Advancing Knowledge. Improving Care.
In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.
What were the key takeaways from the 2026 AAD Annual Meeting? IPC shares updates on diagnostic challenges, psoriasis therapies, and late-breaking research from leading experts.
A new regional collaboration led by IPC and partner organizations aims to improve diagnosis, treatment, and care coordination for psoriasis and psoriatic arthritis across Latin America.
IPC recognizes its 2025 Fellows as IPC Jr. Councilors following the completion of their fellowship. This transition recognizes their contributions to psoriasis research, education, and global collaboration, and marks their expanded role in the IPC network.
The International Psoriasis Council welcomes Mari Løset and Maxwell Sauder as new Councilors, supporting IPC’s global mission in psoriasis research and care.
In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.
Commentary: Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biological treatment and renal transplanted recipients in maintenance immunosuppressive treatment.
Peter van de Kerkhof, MD, PhD
IPC Chief Medical Officer
The Netherlands
Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biological treatment and renal transplanted recipients in maintenance immunosuppressive treatment. Gisondi P, Zaza G, Del Giglio M, Rossi M, Iacono V, Girolomoni G, R. Journal of the American Academy of Dermatology (2020), DOI: https://doi.org/10.1016/ j.jaad.2020.04.085.
COMMENTARY
The treatment of patients with psoriasis has been challenged by the COVID 19 pandemic. In March 2020, with a lack of data allowing an evidence-based approach, IPC formulated a statement urging physicians to discontinue immunosuppressive treatments in patients with active COVID-19 disease. For psoriasis patients with no signs or symptoms of COVID-19, decisions about continuing treatment needed to be taken on a case by case basis, balancing risk with benefit.
I would like to draw your attention to a publication by Paulo Gisondi from Verona on the risk of hospitalization and death from COVID-19 in psoriatic patients receiving biological treatments (980 patients) and renal transplant recipients on immunosuppressive treatment (247 patients).
No psoriatic patients were hospitalized or died for the reason of COVID 19 and only one kidney transplant recipient died. In the general population of Verona, 0.28% of the COVID-19 patients were hospitalized or died. The average age of the patients with psoriasis and renal transplant recipients was 56 and 57 years respectively. 39 % of the psoriasis patients were obese and 12% had diabetes and cardiovascular disease. The authors indicated several limitations of the study. Nevertheless, the study provides important early information.
At present dermatologists are collecting information in COVID registries. IPC is pleased to be a partner on the PsoProtect registry for psoriasis and COVID-19 positive patients. Please consider submitting a case or cases to the registry as it is of utmost importance that we collect the data from patients with psoriasis suffering from COVID-19.
Disclaimer: Views expressed in this commentary are those of the author and do not necessarily represent the position of the International Psoriasis Council or its Board of Directors.
Categories
Recent Posts
Next Generation of Leaders: 2025 IPC Fellows Transition to Jr. Councilors
Highlights from the 2026 American Academy of Dermatology (AAD) Annual Meeting: Diagnostic Complexity, Therapeutic Advances, and Emerging Research
First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study
Also Read
Focus on Psoriasis: Highlights from the 2025 EADV Congress
At the 2025 EADV Annual Meeting in Paris, experts shared new insights into psoriasis diagnosis, symptoms, and treatment. Highlights include the IPC Symposium, Free Communication sessions, and results from pivotal clinical trials on emerging oral peptides, IL-23 inhibitors, and dose-optimization strategies.
Focus on Psoriasis: Highlights from the 2025 Society for Investigative Dermatology (SID) Annual Meeting
IPC’s 2025 SID Congress Report highlights the most impactful psoriasis sessions, covering novel cell-biology insights, neuroimmune mechanisms, metabolic and senescence pathways, and emerging therapies from leading experts.
WHO Academy: Free Psoriasis Course Now Available
Discover the new free psoriasis course on WHOAcademy, created by IPC and IFPA for the WHO. Enhance your knowledge of psoriasis epidemiology, diagnosis, and management.
Subscribe to the IPC Newsletter